转移性去势敏感性前列腺癌的同源重组修复突变、二代测序检测与治疗进展的种族差异
本研究基于美国Flatiron Health-Foundation Medicine数据库,评估了1121例接受HRR检测的mCSPC患者的NGS检测率和至下次治疗时间(TTNT)。结果显示HRR突变率在White、非White和Black患者中分别为17.4%、16.5%和15.2%,非White患者TTNT最短(中位17.0个月),Black患者最长(21.2个月)。尽管NGS检测率从2018年至2023年整体上升且种族差异缩小,但总体检测率仍不理想,多数患者在24个月内进展至下次治疗。
要点
- mCSPC患者HRR突变率约15-17%,BRCA1/2突变率约10-13%。
- 非White患者中位TTNT为17.0个月,短于White(19.2)和Black(21.2)患者。
- NGS检测率从2018年Black患者4.2%升至2023年各组约29.8%,但总体仍不理想。
核心结论
- 尽管NGS检测率近年上升且种族差异缩小,但mCSPC患者总体及各族裔检测率仍不可接受,多数患者在24个月内进展至下次治疗。
研究设计与样本
- 基于美国Flatiron Health-Foundation Medicine Metastatic PC Clinico-Genomic数据库(2011年1月1日至2022年12月31日)和Core Registry(2013年1月1日至2023年12月31日)的回顾性队列研究。
- 纳入2018年1月1日后启动mCSPC治疗且接受HRR检测的1121例患者。
主要发现
- HRR(BRCA1/2)突变率:White患者17.4%(12.7%),非White患者16.5%(10.9%),Black患者15.2%(9.7%)。
- 中位TTNT(月):非White患者17.0(24个月内进展至下次治疗比例60.6%),White患者19.2(56.1%),Black患者21.2(54.7%)。
- 2018年Black患者NGS检测率为4.2%,低于White患者;2023年整体检测率升至29.8%,种族间数值上可比。
临床怎么用
- 应提高mCSPC患者HRR检测率,尤其在非White和Black患者中,以指导治疗决策。
- 检测率上升但总体仍低,需关注多数患者在24个月内进展至下次治疗的现实。
局限性
- 回顾性数据库研究,可能存在选择偏倚和信息偏倚。
- TTNT为描述性分析,未进行统计学比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe next-generation sequencing (NGS) testing rates for deleterious homologous recombination repair (HRR) mutations and time-to-next-treatment (TTNT) among US patients with metastatic castration-sensitive prostate cancer (mCSPC). METHODS: Data from oncology centers included in the nationwide (US-based) Flatiron Health-Foundation Medicine, Inc. Metastatic PC Clinico-Genomic Database (January 1, 2011 to December 31, 2022) and Core Registry (January 1, 2013 to December 31, 2023) were evaluated. Patients who initiated treatment for mCSPC (index date) after January 1, 2018 and received an HRR alteration test were included. TTNT and NGS testing patterns were described overall and among White, non-White (ie, Black, Asian, Hispanic, other), and Black patient subgroups. TTNT was assessed using Kaplan-Meier analyses and annual NGS testing rates were assessed from 2018 to 2023 using the Core Registry. RESULTS: In total, 1121 HRR-tested patients with mCSPC were included. HRR (BRCA1/2) alterations were observed among 17.4% (12.7%) of White patients, 16.5% (10.9%) of non-White patients, and 15.2% (9.7%) of Black patients. Non-White patients had the shortest median (months) TTNT (17.0; 60.6% with next treatment by 24 months), followed by White (19.2; 56.1% with next treatment by 24 months) and Black patients (21.2; 54.7% with next treatment by 24 months). Although Black patients had descriptively lower testing rates than White patients in 2018 (4.2%), the rates increased overall and became numerically comparable between racial groups by 2023 (29.8%). CONCLUSION: Although NGS testing rates have increased, with less disparity in most recent years, the testing rates are unacceptable for patients with mCSPC, overall and across racial groups, with the majority of patients progressing to the next treatment by 24 months. Tweet (121/125 characters including spaces; required): Next-generation sequencing use for metastatic castration-resistant prostate cancer remains suboptimal, regardless of race.
引用
- Bilen MA, Shore N, Burbage S, et al. Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer. Urology. 2026. PMID: 41620128. doi:10.1016/j.urology.2026.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。